ClinicalTrials.gg
Active, not recruitingNCT06654791Updated Nov 27, 2024

Mass Balance Clinical Trial of SIM0270

A Phase 1 interventional study of [14C] SIM0270 Oral Preparation in Healthy Participants, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a single-center, non-randomized, open-label, single-cohort, single-dose phase I clinical study in healthy Chinese adult male subjects.

Read the detailed description

The main objectives of this study were as follows:

  1. To quantitatively analyze the total radioactivity in excreta of healthy subjects after a single oral administration of [14C]SIM0270, and to obtain the data of human radioactive excretion rate and main excretion routes.
  2. After a single oral administration of [14C]SIM0270 in healthy subjects, radioactive metabolite profiles in plasma, urine and feces were investigated to identify metabolites, and the metabolic pathway, main metabolites and elimination pathway of SIM0270 in human body were determined.
  3. The total radioactivity in whole blood and plasma of healthy subjects after a single oral administration of [14C]SIM0270 was quantitatively analyzed, the pharmacokinetic characteristics of total radioactivity in plasma were evaluated, and the distribution of total radioactivity in whole blood and plasma was investigated.
02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd. is the lead sponsor of 78 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects fully understand the test content, process and possible adverse reactions, voluntarily sign , have good communication with the researchers, and can complete all the test procedures in accordance with the protocol.
  2. Chinese male, aged between 18 and 45 years old (including the critical value, subject to the signing of the informed consent).
  3. Weight ≥50.0kg, and (BMI) between 19.0 and 26.0 kg/m2 (including the cut-off value).

Exclusion criteria

Exclusion Criteria:

Clinical examination:

  1. Patients who have undergone physical examination, vital signs, laboratory examination (blood routine, blood biochemistry, thyroid function, coagulation function, urine routine, stool analysis), vision and eye examination (slit-lamp, intraocular pressure and fundus photography), X-ray chest film (anterior and lateral), abdominal B-ultrasound (liver, bile, pancreas, spleen and kidney) and other abnormal examinations with clinical significance;
  2. Patients with abnormal 12-lead and clinical significance (including but not limited to: complete left bundle branch block; Right bundle branch block; First, second, or third degree heart block), or > 450 ms after correction using the Fridericia formula (QTcF=QT / {(60/ heart rate)\^0.33});
  3. surface antigen, antibody, antibody or syphilis antibody positive;

    Medication history:

  4. Those who have used prescription drugs, non-prescription drugs, health drugs or including western medicines or proprietary Chinese medicines within 14 days before the screening period;
  5. Those who participated in any clinical trial and received the experimental drug or medical device intervention within 3 months prior to the screening period;
  6. Any drug with a strong/medium acting inhibitor or a strong/medium acting inducer of in the 4 weeks prior to enrollment (see Appendix 1).

    Disease history and surgical history:

  7. Have been or are currently suffering from any clinically serious disease of the cardiovascular system, digestive system, respiratory system, endocrine system, nervous system, hematology, immunology, skin, tumor, psychiatric and metabolic abnormalities, or any other disease or physiological condition that can interfere with the test results;
  8. The presence of risk factors for Torsade de Pointes (such as a history of heart failure, hypokalemia, or a family history of prolonged QT syndrome), or a history of sick sinus syndrome, or a history of previous myocardial infarction;
  9. Patients who have undergone major surgery or whose surgical incision has not fully healed within the 6 months prior to the screening period, including but not limited to any surgery with significant bleeding risk, extended period of general anesthesia or open or significant traumatic injury (except surgery for recovered appendicitis or proctocele);
  10. Severe allergy, including allergy to the drug or any in the investigational drug, allergy to two or more other drugs or food ingredients;
  11. Those who have special requirements for diet and cannot comply with a unified diet;
  12. Perianal disease with regular/bleeding stool;
  13. Habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease;

    Living habits:

  14. Irregular or difficult bowel movements, or other circumstances as assessed by the investigator that affect the collection of stool samples;
  15. Binge drinking or regular drinking in the six months preceding the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or positive alcohol breath test at screening period;
  16. Smokers who smoked more than 5 cigarettes per day or habitually used nicotine-containing products in the 3 months before the screening period and could not quit during the trial;
  17. Drug abuse or dependence, urine drug abuse screening positive;
  18. Habitual drinking of grapefruit juice or excessive tea (more than 8 cups a day, 1 cup =250 mL), excessive intake of caffeine (more than 3 cups a day coffee, 1 cup =250 mL), and unable to abstain during the trial;

    Others:

  19. Workers who require prolonged exposure to radioactive conditions; Or had significant radiation exposure (≥2 chest/abdominal CT, or ≥3 other types of X-rays) within 1 year prior to the test or participated in a radiopharmaceutically labeled test within 1 year;
  20. The subject who is fertile has a birth plan or sperm donation plan within 1 year after the signing of the , or the subject and his or her partner do not agree to take effective measures (such as condoms, contraceptive sponges, contraceptive gels, contraceptive membranes, intrauterine devices, oral or injectable contraceptives, subcutaneous implants, etc.);
  21. Those who have lost blood or donated blood up to 400 mL within 3 months before the screening period, or received blood transfusions within 1 month;
  22. Subjects who have any other factors deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Other
    [14C]SIM0270 group

    Single arm study

    Drug: [14C] SIM0270 Oral Preparation

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]SIM0270 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period

    Following a single oral dose of 60 milligrams/150μCi of \[14C\]SIM0270, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting.

    Time frame: From Day 1 to Day 44

  2. Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]SIM0270 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period

    Following a single oral dose of 60 milligrams/150μCi of \[14C\]SIM0270, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting.

    Time frame: From Day 1 to Day 44

  3. Maximum 0bserved Concentration (Cmax), Estimated for SIM0270 in Plasma and for Total Radioactivity in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of SIM0270 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: From 0 to 432 hours

  4. Time to Maximum 0served Concentration (Tmax), Estimated for SIM0270 in Plasma and for Total Radioactivity in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of SIM0270 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: From 0 to 432 hours

  5. Area Under the Concentration-Time Curve From Time 0 to 432 Hours AUC(0-432), Estimated for SIM0270 in Plasma and for Total Radioactivity in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of SIM0270 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: From 0 to 432 hours

  6. Terminal Elimination Half-Life (t1/2), Estimated for SIM0270 in Plasma and for Total Radioactivity in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of SIM0270 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: From 0 to 432 hours

Secondary outcomes

  1. The incidence of Adverse events

    The incidence and grading of adverse events

    Time frame: From signing ICF until 14 days after departure from the study.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Mar 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 23, 2024
StartActual
Oct 17, 2024
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 31, 2025
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06654791
Collaborators
Nanjing Zaiming Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Oct 17, 2024
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Nov 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SIM0270

Start the discussion